Tuesday, January 25, 2022 12:34:11 PM
NASDAQ is gonna be very bad for this company.
As the company said, the company doesn’t anticipate generating any revenue from their cancer & Covid drugs in the foreseeable future.
The company will continue to do stock offerings to dilute and reverse splits, all of which will destroy investor value.
The company admits that it may not even be around in the future. Who wants to invest in a company that could disappear soon and has no foreseeable sources of revenue beyond some vitamins on Amazon?
They will continue to do massive splits and stock offerings, which destroys investors, and there will continue to be a stream of chumps who get suckered into buying this trash.
As the company said, the company doesn’t anticipate generating any revenue from their cancer & Covid drugs in the foreseeable future.
The company will continue to do stock offerings to dilute and reverse splits, all of which will destroy investor value.
The company admits that it may not even be around in the future. Who wants to invest in a company that could disappear soon and has no foreseeable sources of revenue beyond some vitamins on Amazon?
They will continue to do massive splits and stock offerings, which destroys investors, and there will continue to be a stream of chumps who get suckered into buying this trash.
Recent SBFM News
- Sunshine Biopharma Announces Canadian Approval for Rivaroxaban, a Generic Form of Xarelto(R) • ACCESS Newswire • 06/01/2026 12:00:00 PM
- Sunshine Biopharma Announces Issuance of U.S. Patent 12,624,066 B2 Covering Novel Coronavirus Treatment Technology • ACCESS Newswire • 05/29/2026 12:00:00 PM
- Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing • ACCESS Newswire • 05/28/2026 01:00:00 PM
- Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Amoxicillin • ACCESS Newswire • 05/21/2026 11:00:00 AM
- Sunshine Biopharma Inc. Announces Closing of up to $18.0 Million Public Offering • ACCESS Newswire • 05/19/2026 04:05:00 PM
- Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering • ACCESS Newswire • 05/18/2026 04:15:00 PM
- Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year • ACCESS Newswire • 04/06/2026 12:30:00 PM
- Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea • ACCESS Newswire • 10/28/2025 11:45:00 AM
- Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline • ACCESS Newswire • 10/20/2025 11:45:00 AM
- Sunshine Biopharma Launches Cholesterol Fighting Medicine Pravastatin • ACCESS Newswire • 10/16/2025 11:45:00 AM
- Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience • ACCESS Newswire • 10/14/2025 11:00:00 AM
- Sunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus Infections • ACCESS Newswire • 10/09/2025 12:00:00 PM
